Buprenorphine 0.4 mg – Effective Partial Opioid Agonist

Product Overview

Buprenorphine 0.4 mg is a potent partial agonist of the mu-opioid receptor used for effective pain management and opioid dependence treatment. This sublingual formulation offers prolonged analgesic effects while minimizing common opioid-associated risks such as respiratory depression and overdose. Its unique pharmacological profile includes a ceiling effect that enhances safety, making it suitable for long-term use in patients requiring opioid therapy.

Manufactured by Vonage Pharma under strict GMP standards, Buprenorphine 0.4 mg guarantees premium quality and consistent efficacy.

Mechanism of Action

Buprenorphine acts as a partial agonist at mu-opioid receptors with high receptor affinity and slow dissociation, producing effective analgesia with less risk of respiratory depression compared to full agonists. It also acts as a weak antagonist at kappa opioid receptors, which may contribute to mood stabilization.

Due to its partial agonism, buprenorphine exhibits a ceiling effect for respiratory depression and euphoria, reducing overdose potential. The sublingual route ensures rapid absorption, bypassing first-pass metabolism, and achieving peak effect within 3 to 4 hours.

Indications and Uses

• Pain management in chronic conditions requiring opioid therapy

• Treatment of opioid dependence and withdrawal symptoms

• Suitable for patients needing opioid substitution therapy or long-term analgesia

• Use in tapering or maintenance phases of opioid addiction treatment

Dosage and Administration:

Administered sublingually; place the tablet under the tongue until fully dissolved (up to 10 minutes). Dosing should be tailored to individual patient needs based on clinical guidelines.

Buprenorphine is available in several formulations in Pluvia Endo, including:

• Buprenorphine API: This formulation is used in various delivery methods, including tablets and implants:
  • Buprenorphine Base
  • Buprenorphine Hydrochloride
• Buprenorphine Sublingual: Buprenorphine Tablets allow for rapid onset of action as the medication dissolves under the tongue:
  • Buprenorphine Sublingual 0.4 mg
  • Buprenorphine Sublingual 2 mg
  • Buprenorphine Sublingual 8 mg
• Intermediates:
  • N-Methylnorbuprenorphine 3-methyl ether
  • (5R,6R,7S,9R,13S,14S,20S)-17-Cyclopropylmethyl-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-α-methyl-6,14-ethanomorphinan-7-methanol

Contraindications:

• Hypersensitivity to buprenorphine or any components of the formulation.
• Significant respiratory depression or acute/severe asthma in an unmonitored setting.

Warnings and Precautions:

Use with caution in patients with:

• Cardiovascular disease
• Hepatic impairment
• Renal impairment
• Respiratory compromise

Side Effects:

Common side effects may include:

• Nausea
• Vomiting
• Constipation
• Dizziness

Packaging and Storage

• Available as sublingual tablets with 0.4 mg strength

• Packaging includes blister packs with 14 or 28 tablets

• Store in a cool, dry place, away from direct light and moisture

Why Choose Vonage Pharma’s Buprenorphine 0.4 mg?

Vonage Pharma ensures every batch of Buprenorphine 0.4 mg meets strict GMP guidelines, delivering reliable pain relief and dependence treatment solutions. Our product supports healthcare professionals with consistent quality, patient safety, and expert clinical service.

For more information or to place an order, please contact us today!